Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2006-11-07
2006-11-07
Le, Long V. (Department: 1641)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S405000, C530S409000, C540S474000, C436S545000, C424S009360, C424S009364, C588S020000, C588S318000, C435S188000
Reexamination Certificate
active
07132513
ABSTRACT:
The invention concerns a ligand comprising wherein n is an integer from 1 to 5, X represents —NO2, —NH2, —NCS, —NHCOCH2-Z. NHCO—W—COCNHS, —NH-Q, —NHCS-Q, —NHCOCH2-Q, or —NHCO(CH2)m ?-Q where Q is an hapten chosen from the group consisting of steroids, enzymes, proteins, monoclonal antibodies, chimeric antibodies, or fragments thereof or any activated linker ready for coupling reaction, Y is CO2H or PO3H2W is —(CH2)m— m is an integer from 1 to 10. Z is chloride, bromide or iodine
REFERENCES:
patent: 5435990 (1995-07-01), Cheng et al.
patent: 6696551 (2004-02-01), Brechbiel et al.
patent: WO 89/11475 (1989-11-01), None
patent: WO 95/20580 (1995-08-01), None
patent: WO 00/59896 (2000-10-01), None
Takenochi et al, “Preperation of bifunctional macrocyclic chelate ligands.” Japanese Patent # 03197468, 1991, HCAPLUS Accession No. 1992:128980, Document No. 116:128980.
Couturier, O., et al., “Validation of 213-Bi-alpha radioimmunotherapy for multiple myeloma”. Clin. Cancer. Res., vol. 5, pp. 3165-3170, 1999.
Huneke, R. B., et al., “Effective alpha-particle-mediated Radioimmunotherapy of Murine Leukemia”. Cancer Res., vol. 52, pp. 5818-5820, 1992.
Kozak, R. W., et al., “Bismuth-212-labeled anti-Tac monoclonal antibody: alpha-particle-emitting radionuclides as modalities for radioimmunotherapy”. Proc. Natl. Acad. Sci. USA, vol. 83, pp. 474-478, 1986.
Macklis, R. M., et al., “Radioimmunotherapy with Alpha-Particle-Emitting Immunoconjugates”. Science, vol. 240, pp. 1024-1026, 1988.
Kaspersen, F.M., et al., “Cytotoxicity of213Bi- and225Ac-immunoconjugates”. Nucl. Med. Commun., vol. 16, pp. 468-476, 1995.
Kennel, S. J. “Radioimmunotherapy of micrometastases in lung with vascular targeted 213-Bi”British Journal of Cancer. vol. 80 (1/2), pp. 175-184, 1999.
(Previously Submitted) Kaspersen, F.M. “Cytotoxicity of 213 Bi- and 225 Ac-immunoconjugates”Nuclear Medicine Communications. vol. 16, pp. 468-476, 1995.
Davis, K.A. “Comparison of 225-Actinium Chelates: Tissue Distribution and Radiotoxicity”Nuclear Medicine&Biology, vol. 26, pp. 581-589, 1999.
Grote Gransey, M.H.B. “Conjugation, Immunoreactivity, and Immunogenicity of Calix[4 ]arenas; Model Study to Potential Calix[4 ]arene-Based Ac3+ Chelators”Bioconjugate Chem. vol. 10, pp. 613-623, 1999.
Deal, Kim A., et al., “Improved in Vivo Stability of Actinium-225 Macrocyclic Complexes”. J. Med. Chem., 42, 2988-2992, (1999).
Takenochi, K., et al., “Preparation of bifunctional macrocyclic chelate ligands”. Chemical Abstracts, vol. 116, No. 13, Abstract No. 128980, (Mar. 30, 1992).
Apostolidis Christos
Gestin Jean-François
Ouadi Ali
European Community
Haq Shafiqul
Harkins Tanya E.
INSERM Insitut National de la Santé et de la Recherche M&#x
Le Long V.
LandOfFree
Bifunctional chelating agent does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Bifunctional chelating agent, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Bifunctional chelating agent will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3703915